Supernus Pharmaceuticals, Inc. - SUPN STOCK NEWS

Supernus Pharmaceuticals reported strong Q3 2024 financial results with total revenues of $175.7 million, up 14% year-over-year. Qelbree sales increased 68% to $62.4 million, while GOCOVRI sales grew 8% to $35.6 million. Operating earnings reached $40.9 million, compared to $8.1 million in Q3 2023. The company raised its full-year 2024 guidance, now expecting total revenues of $630-$650 million and operating earnings of $50-$65 million. Key pipeline developments include positive Phase 2a results for SPN-820 in major depressive disorder and progress in SPN-817's development for epilepsy.

Supernus Pharmaceuticals (SUPN) presented promising Phase 2a study results for SPN-820 in treating Major Depressive Disorder at Psych Congress 2024. The study, involving 40 participants, demonstrated significant improvements in depressive symptoms. Key findings include a rapid MADRS response rate reaching 84.2% by Day 10, an 80% decrease in suicidal ideation, and clinically meaningful improvements in HAM-D6 and MADRS scores. The drug was well-tolerated with mostly mild to moderate side effects, showing potential as a first-in-class, oral treatment for depression with rapid-acting properties.

Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company focused on central nervous system (CNS) diseases, has announced its plans to report third quarter 2024 financial and business results on November 4, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will lead the call, presenting the results and answering questions. Investors can access the live webcast through the company's Investor Relations website. Pre-registration is available for participants, who will receive a personalized dial-in number and conference code.

Supernus Pharmaceuticals (Nasdaq: SUPN) announced promising data from its open-label Phase 2a study of SPN-820 in adults with major depressive disorder. The study demonstrated a rapid and substantial decrease in depressive symptoms, with clinically meaningful improvements observed in both HAM-D6 and MADRS scores. Key findings include:

- Improvement of -6.1 at two hours and -9.6 at Day 10 on HAM-D6 total score
- Improvement of -16.6 at four hours and -22.9 at Day 10 on MADRS total score
- 80% decrease in suicidal ideation
- Well-tolerated with few adverse events

SPN-820, a novel intracellular modulator of mTORC1, shows potential as a treatment option for depression. Supernus expects to complete enrollment in the Phase 2b randomized double-blind placebo-controlled study in November, with topline results anticipated in the first half of 2025.

Supernus Pharmaceuticals (Nasdaq: SUPN) has announced a webcast and conference call scheduled for Thursday, October 17, 2024, at 4:30 p.m. ET. The purpose of this event is to review data from the open-label Phase 2a study of SPN-820, a treatment for major depressive disorder. The company, which focuses on developing and commercializing products for central nervous system (CNS) diseases, will provide a live webcast with presentation slides accessible via a specific link or through the Events & Presentations section of their Investor Relations website.

Following management's prepared remarks and discussion of the interim trial results, there will be a Q&A session. Participants can pre-register for the call and will receive a personalized dial-in number. A replay of the call will be available on the company's website, with the webcast remaining accessible for 60 days after the live call.

Supernus Pharmaceuticals continues its collaboration with actress Busy Philipps to raise awareness about ADHD in women and promote Qelbree®, a non-stimulant ADHD treatment. Philipps shares her personal experience with ADHD and how Qelbree has helped manage her symptoms. The campaign aims to empower women to advocate for their ADHD care, especially as ADHD Awareness Month approaches.

Qelbree is a once-daily non-stimulant medication approved for patients 6 years and older with ADHD. It's the first non-stimulant approved for adults with ADHD in 20 years. The drug has no evidence of abuse or misuse and can be refilled without needing a new prescription each month.

The press release includes important safety information, noting that Qelbree may increase suicidal thoughts and actions in some patients. It also mentions potential side effects and drug interactions.

Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit. The company's President and CEO, Jack Khattar, will engage in a virtual fireside chat on Thursday, September 26, 2024, at 8:40 a.m. ET.

Interested parties can access a live webcast of the presentation through a provided link or by visiting the Events & Presentations section in the Investor Relations area of the company's website at www.supernus.com. An archived replay of the webcast will remain available on the company's website for 60 days following the conference.

Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in the 2024 Wells Fargo Healthcare Conference. Jack Khattar, President and CEO, will engage in a fireside chat on September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts.

Investors can arrange meetings with company management through the Wells Fargo conference coordinator. A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for 60 days post-conference. This event provides an opportunity for Supernus to showcase its developments in CNS treatments to potential investors and industry professionals.

Supernus Pharmaceuticals (Nasdaq: SUPN) has announced that the FDA has accepted the resubmission of the new drug application (NDA) for SPN-830, its apomorphine infusion device. This device is designed for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease. The FDA has set a PDUFA target action date of February 1, 2025 for the review of the application. This development marks a significant step forward in Supernus's efforts to bring a new treatment option to market for Parkinson's disease patients experiencing motor fluctuations.